华森制药
(002907)
| 流通市值：45.44亿 | | | 总市值：63.27亿 |
| 流通股本：3.00亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 302,968,947.78 | 284,553,384.23 | 297,078,384.94 | 456,552,929.38 |
| 交易性金融资产 | 290,429,424.65 | 240,988,054.8 | 250,499,397.25 | 120,606,082.18 |
| 应收票据及应收账款 | 282,898,497.24 | 309,601,482.71 | 323,172,398.54 | 272,703,800.2 |
| 其中：应收票据 | 75,572,562.2 | 97,493,415.05 | 102,183,107.59 | 97,861,218.9 |
| 应收账款 | 207,325,935.04 | 212,108,067.66 | 220,989,290.95 | 174,842,581.3 |
| 预付款项 | 82,142,519.01 | 44,282,952.09 | 7,324,738.64 | 7,884,495.06 |
| 其他应收款合计 | 4,511,387.87 | 4,416,753.5 | 4,585,305.96 | 2,891,877.67 |
| 存货 | 124,093,776.96 | 120,784,309.42 | 127,823,788.51 | 140,125,411.63 |
| 其他流动资产 | 982,133.19 | 83,022,406.66 | 80,871,549.17 | 30,579,915.16 |
| 流动资产合计 | 1,089,026,686.7 | 1,088,649,343.41 | 1,091,355,563.01 | 1,031,344,511.28 |
| 非流动资产: | | | | |
| 长期股权投资 | - | 0 | 14,188,853.36 | 15,414,034.45 |
| 其他非流动金融资产 | 76,919,000 | 76,919,000 | 78,234,500 | 78,234,500 |
| 投资性房地产 | 65,341,641.85 | 66,157,296.78 | 67,054,591.2 | 68,327,959.4 |
| 固定资产 | 487,542,747.49 | 501,092,380.68 | 511,681,804.16 | 527,896,179.7 |
| 在建工程 | 9,280,829.79 | 9,280,829.79 | 10,529,968.44 | 10,190,518.9 |
| 使用权资产 | 604,920.58 | 296,022.41 | 270,427.16 | 143,168.7 |
| 无形资产 | 213,314,139.59 | 214,779,462.58 | 121,085,857.35 | 125,888,406.4 |
| 开发支出 | 29,084,781.51 | 33,610,008.64 | 32,362,755.51 | 30,270,209.78 |
| 长期待摊费用 | 8,018,013.17 | 9,007,897.75 | 6,519,283.04 | 6,699,093.67 |
| 递延所得税资产 | 13,528,767.23 | 15,176,926.25 | 14,922,852.61 | 17,256,757.2 |
| 其他非流动资产 | 5,039,239.14 | 5,763,843.14 | 5,355,936.63 | 5,884,249.52 |
| 非流动资产合计 | 908,674,080.35 | 932,083,668.02 | 862,206,829.46 | 886,205,077.72 |
| 资产总计 | 1,997,700,767.05 | 2,020,733,011.43 | 1,953,562,392.47 | 1,917,549,589 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 65,660,673.69 | 73,468,962.62 | 68,465,269.6 | 64,363,225.38 |
| 应付账款 | 65,660,673.69 | 73,468,962.62 | 68,465,269.6 | 64,363,225.38 |
| 预收款项 | 1,604,087.28 | 1,145,275.85 | 946,377.5 | 1,047,147.07 |
| 合同负债 | 6,950,622.58 | 10,802,634.02 | 4,550,742.76 | 8,688,989.46 |
| 应付职工薪酬 | 8,599,603.29 | 9,669,969.91 | 8,013,586.9 | 25,313,927.98 |
| 应交税费 | 10,216,523.36 | 7,340,347.15 | 18,759,671.62 | 11,797,879.99 |
| 其他应付款合计 | 101,744,703.29 | 114,640,789.85 | 108,523,465.25 | 99,573,492.18 |
| 一年内到期的非流动负债 | 37,669,345.58 | 38,137,252.38 | 86,841.42 | 86,841.42 |
| 其他流动负债 | 1,021,816.32 | 1,424,933.81 | 598,423.17 | 1,162,637.44 |
| 流动负债合计 | 233,467,375.39 | 256,630,165.59 | 209,944,378.22 | 212,034,140.92 |
| 非流动负债: | | | | |
| 租赁负债 | 1,170,243.98 | 156,587.65 | 155,900.21 | 40,720.14 |
| 递延收益 | 39,990,464.71 | 40,368,019.6 | 40,906,749.8 | 42,992,848.24 |
| 递延所得税负债 | 13,035,379.01 | 14,719,828.92 | 2,058,277.14 | 2,483,601.32 |
| 非流动负债合计 | 54,196,087.7 | 55,244,436.17 | 43,120,927.15 | 45,517,169.7 |
| 负债合计 | 287,663,463.09 | 311,874,601.76 | 253,065,305.37 | 257,551,310.62 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 417,596,314 | 417,596,314 | 417,596,314 | 417,596,314 |
| 资本公积 | 451,167,992.7 | 451,038,872.02 | 459,480,719.05 | 459,331,051.85 |
| 其他综合收益 | 128,990.24 | 160,590.06 | 172,255.78 | 178,326.64 |
| 盈余公积 | 101,260,953.57 | 101,260,953.57 | 101,260,953.57 | 101,260,953.57 |
| 未分配利润 | 718,591,552.92 | 714,702,333.05 | 721,986,844.7 | 681,631,632.32 |
| 归属于母公司股东权益合计 | 1,688,745,803.43 | 1,684,759,062.7 | 1,700,497,087.1 | 1,659,998,278.38 |
| 少数股东权益 | 21,291,500.53 | 24,099,346.97 | - | - |
| 股东权益合计 | 1,710,037,303.96 | 1,708,858,409.67 | 1,700,497,087.1 | 1,659,998,278.38 |
| 负债和股东权益合计 | 1,997,700,767.05 | 2,020,733,011.43 | 1,953,562,392.47 | 1,917,549,589 |
| 公告日期 | 2025-10-29 | 2025-08-22 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |